Abstract
Growing interest in minimally invasive uterine-sparing conservative surgery for managing uterine fibroids has made radiofrequency ablation (RFA) a popular procedure. The two most common approaches are a laparoscopic RFA (LAP-RFA) technique—the Acessa ProVu® System (Acessa Health Inc., Austin, TX, USA)—and transcervical fibroid ablation (TFA)—the Sonata® System (Gynesonics, Redwood City, CA, USA). Positive impacts on decreasing uterine size, improving patients' quality of life, and inducing uncomplicated pregnancy outcomes, support RFA as an option to manage fibroids in the right patients. However, although these procedures are promising, they are not yet approved by the U.S. Food and Drug Administration for patients seeking treatment for infertility. This article briefly addresses updates in the current literature on these 2 procedures . (J GYNECOL SURG 40:10)
Get full access to this article
View all access options for this article.
